2028, Food and Drug Administration and Physicians

An increasing impact of BCMA-targeting biologics in multiple myeloma

Pharmaceutical Technology

SEPTEMBER 2, 2022

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration

Food and Drug Administration FDA Sales Marketing

A history of blood cancer treatment

pharmaphorum

SEPTEMBER 13, 2022

After attempts to treat McBean’s symptoms – through cupping, applying leeches for maintenance therapy, and therapeutic phlebotomy – proved unsuccessful, his physician, Dr Thomas Watson, prescribed steel and quinine, while a sample of his urine was sent to chemical pathologist Henry Bence Jones.

Food and Drug Administration

Food and Drug Administration Patients Engineering Physicians

Pharma Rep Focus

An increasing impact of BCMA-targeting biologics in multiple myeloma

A history of blood cancer treatment

Webinars

Stay Connected